{'fraction_non_alphanumeric': 0.03507194244604316, 'fraction_numerical': 0.008992805755395683, 'mean_word_length': 6.469798657718121, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Anticonvulsant activity of some vanilloid receptor

Background: Vanilloid receptors 1 (VR 1), a group of transient receptor potential channels family was cloned in 1997. They were found to be a potential target for treatment of different acute and chronic pain disorder. Recently these receptors were reported to be involved in several pathological conditions. Objectives: The present study aimed to investigate the potential anticonvulsant activity of five vanilloidal agonists (capsaicin, nonivamide, zingerone, dehydrozingerone and 6-gingerol). Methods: Experimental animal model of pentylenetetrazole (PTZ) induced seizure was used to investigate the potential anticonvulsant activity of capsaicin, nonivamide, zingerone, dehydrozingerone and 6-gingerol. Results: The data obtained showed that, all tested compounds (capsaicin, nonivamide, zingerone, dehydrozingerone and 6-gingerol) possess dose dependant anticonvulsant activity. Conclusion: The five vanilloidal agonists; capsaicin, nonivamide, zingerone, dehydrozingerone and 6-gingerol exhibit anticonvulsant activity and may find clinical applications.